Company News

October 05

Gmax to Present at the International Diabetes Federation Congress 2017

October 5, 2017, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today...


June 1

GMA102/105 entered phase 2 clinical trial in Australia and New Zealand

June 1, 2017, GMA102/105 has started phase Ib/IIa clinical trial in Australia and New Zealand.

April 6

GMA301 was selected as “National Mega-Innovative Program”

April 6, 2017, GMA301 was selected as the “National Mega-Innovative Program” for the 13th Five Year Plan.

September 30

GMA102 IND registration accepted by CDE

September 30, 2016, CDE has accepted the IND registration of GMA 102.


April 30

GMA102 started phase 1 clinical trial in Australia

April 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia.



7 Records 12